TY - JOUR
T1 - Outcome of unrelated umbilical cord blood transplantation in 88 patients with primary immunodeficiency in Japan
AU - Morio, Tomohiro
AU - Atsuta, Yoshiko
AU - Tomizawa, Daisuke
AU - Nagamura-Inoue, Tokiko
AU - Kato, Koji
AU - Ariga, Tadashi
AU - Kawa, Keisei
AU - Koike, Kazutoshi
AU - Tauchi, Hisamichi
AU - Kajiwara, Michiko
AU - Hara, Toshiro
AU - Kato, Shunichi
PY - 2011/8
Y1 - 2011/8
N2 - We report the results of umbilical cord blood transplantation (UCBT) performed in 88 patients with primary immunodeficiency (PID) between 1998 and 2008 in Japan; severe combined immunodeficiency (SCID, n=40), Wiskott-Aldrich syndrome (WAS, n=23), chronic granulomatous disease (n=7), severe congenital neutropaenia (SCN, n=5) and other immunodeficiencies (n=13). Five-year overall survival (5-year OS) for all patients was 69% [95% confidence interval (CI), 57-78%], and was 71% and 82% for SCID and WAS, respectively. The main cause of death before day 100 was infection (17/19), while that after day 100 was graft-versus-host disease (GVHD) (5/7). Using multivariate analyses, pre-transplant infection, no conditioning, ≥2 human leucocyte antigen (HLA) mismatches or diagnosis other than SCID, SCN or WAS were all associated with poor prognosis. Reduced-intensity conditioning was associated with decreased overall mortality compared with myeloablative therapy. The cumulative incidence of grade 2-4 acute GVHD at day 100 was 28% (95% CI, 19-38%), and that of chronic GVHD at day 180 was 13% (95% CI, 7-23%). We conclude that UCBT should be considered for PID patients without an HLA-matched sibling. The control of pre-transplant infection and selection of HLA-matched donors will lead to a better outcome.
AB - We report the results of umbilical cord blood transplantation (UCBT) performed in 88 patients with primary immunodeficiency (PID) between 1998 and 2008 in Japan; severe combined immunodeficiency (SCID, n=40), Wiskott-Aldrich syndrome (WAS, n=23), chronic granulomatous disease (n=7), severe congenital neutropaenia (SCN, n=5) and other immunodeficiencies (n=13). Five-year overall survival (5-year OS) for all patients was 69% [95% confidence interval (CI), 57-78%], and was 71% and 82% for SCID and WAS, respectively. The main cause of death before day 100 was infection (17/19), while that after day 100 was graft-versus-host disease (GVHD) (5/7). Using multivariate analyses, pre-transplant infection, no conditioning, ≥2 human leucocyte antigen (HLA) mismatches or diagnosis other than SCID, SCN or WAS were all associated with poor prognosis. Reduced-intensity conditioning was associated with decreased overall mortality compared with myeloablative therapy. The cumulative incidence of grade 2-4 acute GVHD at day 100 was 28% (95% CI, 19-38%), and that of chronic GVHD at day 180 was 13% (95% CI, 7-23%). We conclude that UCBT should be considered for PID patients without an HLA-matched sibling. The control of pre-transplant infection and selection of HLA-matched donors will lead to a better outcome.
UR - http://www.scopus.com/inward/record.url?scp=79960204921&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960204921&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2141.2011.08735.x
DO - 10.1111/j.1365-2141.2011.08735.x
M3 - Article
C2 - 21569009
AN - SCOPUS:79960204921
SN - 0007-1048
VL - 154
SP - 363
EP - 372
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 3
ER -